Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, Merced Dr. Kara E McCloskey Basic Biology V Directed Differentiation of Specialized Endothelial Cells $475,686
University of California, San Francisco Dr. Valerie Marie Weaver Basic Biology V Biophysical Determinants of Early Embryonic Stem Cell Fate Specification $1,186,500
California Institute of Technology Dr. David Anthony Tirrell Basic Biology V Engineered matrices for control of lineage commitment in human pancreatic stem cells $526,896
Salk Institute for Biological Studies Ronald Mark Evans Basic Biology V Metabolically-driven epigenetic changes in iPSC reprogramming $1,491,900
University of California, San Diego Dr. Dianne McKay Basic Biology V Role of intracytoplasmic pattern recognition receptors in HSC engraftment $615,639
Stanford University Dr. Gary Steinberg Basic Biology V Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery $1,178,370
University of California, San Diego Christian Metallo Basic Biology V Metabolic regulation of cardiac differentiation and maturation $1,124,834
University of California, Los Angeles Dr Samantha J Butler Ph.D. Basic Biology V Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate $515,730
Cedars-Sinai Medical Center Paul W Noble Basic Biology V Innate Immune Regulation of Lung Alveolar Stem Cell Renewal in Mouse and Man $617,662
Gladstone Institutes, J. David Sheng Ding PhD Basic Biology V A novel druggable mechanism to safeguard stem cell genome $1,294,495
University of California, San Francisco Dr. Mark S. Anderson Basic Biology V Generation of a functional thymus to induce immune tolerance to stem cell derivatives $1,191,000
University of California, Irvine Dr. Lisa A Flanagan Basic Biology V Molecular basis of plasma membrane characteristics reflecting stem cell fate potential $994,108
University of California, San Diego Maike Sander Basic Biology V Defining links between chromatin state and developmental competence $1,050,300
University of Southern California Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $735,138
University of California, Los Angeles Dr. Denis A Evseenko Dr. Basic Biology V Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes $411,330
University of California, San Diego Miles F Wilkinson Basic Biology V New Regulators of Spermatogonial Stem Cells: RHOX Homeobox Transcription Factors $552,811
University of California, Los Angeles Dr. Lili Yang Basic Biology V Differentiation of Human Hematopoietic Stem Cells into iNKT Cells $614,400
University of California, San Diego Dr. Cornelis Murre Basic Biology V Epigenetic mechanisms that enforce pluripotency in embryonic stem cells $1,160,997
University of California, San Diego Dr. Wei Wang Basic Biology V Systems-level discovery of the regulatory mechanisms directing differentiation of hESC $1,161,000
University of California, San Diego Dr. Lawrence S. B. Goldstein Basic Biology V Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes $1,050,300
University of California, San Diego Dr. David A. Cheresh Basic Biology V CD61-driven stemness program in epithelial cancer $1,161,000
University of California, Berkeley Dr. Andrew Dillin Basic Biology V A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health $1,034,100
Stanford University Xinnan Wang Basic Biology V Misregulated Mitophagy in Parkinsonian Neurodegeneration $1,174,943
University of Southern California Mark Salman Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
University of California, Davis Peter Belafsky Disease Team Therapy Development III Tissue Engineered Recellularized Laryngotracheal Implants $3,181,162
University of California, Los Angeles Dr. Dennis J Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors $5,683,693
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Disease Team Therapy Planning I Stem Cells Secreting GDNF for the Treatment of ALS $63,487